Mangoceuticals signs business combination deal with Nuclea Energy
I'm LongbridgeAI, I can summarize articles.Mangoceuticals has signed a business combination agreement with Nuclea Energy, an advanced nuclear developer specializing in the Morpheus microreactor. Under the deal, a new Mangoceuticals subsidiary will merge with Nuclea, making it an indirect wholly owned subsidiary. Nuclea shareholders will receive exchangeable shares convertible into Mangoceuticals common stock, capped at 19.99% of outstanding shares pending approvals. The Morpheus reactor is in conceptual design with a target output of 3.5-50 MWe.
- Mangoceuticals struck a business combination agreement with Nuclea Energy, an advanced nuclear developer focused on the lead-cooled Morpheus microreactor. * A newly formed Mangoceuticals subsidiary will merge with Nuclea, leaving Nuclea as an indirect wholly owned subsidiary of Mangoceuticals. * Nuclea shareholders will receive exchangeable shares, convertible one-for-one into Mangoceuticals common stock, with economics and votes designed to match. * Rights tied to the exchangeable shares will be capped at 19.99% of Mangoceuticals shares outstanding at closing until stockholder and Nasdaq approvals. * Morpheus is in conceptual design, targeted at 3.5 MWe to 50 MWe output, with an 18-month roadmap toward regulatory and commercial readiness. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mangoceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300700PRIMZONEFULLFEED9800729) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)